"Psilocybin is basically FDA-approved now" / "it's essentially legal" — a belief plausibly reinforced by heavy 2025-2026 news coverage of Compass Pathways' two positive Phase 3 trials, an April 2026 White House executive order fast-tracking psychedelic drug review, FDA priority vouchers issued days later, and new state medical-psilocybin programs in Oregon, Colorado, and New Mexico.
Psilocybin remains a Schedule I controlled substance under the federal Controlled Substances Act with no FDA-approved medical use anywhere in the US as of August 2026. What has actually happened: Compass Pathways' synthetic psilocybin (COMP360) met its primary endpoint in two Phase 3 trials for treatment-resistant depression (COMP005, COMP006, both company press releases pending independent peer review), and the company is pursuing a Q4 2026 NDA submission under an FDA priority voucher — but any resulting approval would apply only to that specific proprietary drug/protocol, not to psilocybin generally or to mushrooms. Separately, three states (Oregon, Colorado, New Mexico) run their own state-regulated programs, but these operate outside, and in legal tension with, federal law; they are not FDA drug approvals and do not change psilocybin's federal status. Even the most rigorously blinded psilocybin RCT to date (Mertens et al. 2026, EPISODE trial) did not meet its own primary efficacy endpoint, underscoring that the evidence base, while genuinely promising, is not as uniformly settled as the momentum narrative suggests.
The gap is regulatory precision, not direction: real momentum (two positive Phase 3 readouts, an executive order, FDA priority vouchers, state programs) is being popularly compressed into 'basically approved/legal,' when federally psilocybin is still Schedule I, is not an approved treatment anywhere in the US, and any future FDA approval would be narrow — one company's specific drug and protocol — not blanket legalization, a green light for general/recreational use, or an endorsement of unregulated mushrooms.
